LIXTE BIOTECHNOLOGY HLDGS IN (LIXT)
Institutional ownership reported to the SEC as of Q2 2023, across 11 quarters.
1
Reporting holders
$205.2K
Reported value
0.0%
Held as options
-8
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| Ethos Financial Group, LLC | $205.2K | 248,084 | 0.07% | 3q | HELD |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2023 | 1 | $205.2K | 248,084 | 0 | 0 | 0 | 0.0% |
| Q1 2023 | 9 | $451.0K | 544,724 | 1 | 4 | 1 | 0.0% |
| Q4 2022 | 12 | $340.2K | 668,441 | 4 | 1 | 1 | 0.0% |
| Q3 2022 | 13 | $363.0K | 648,856 | 1 | 5 | 1 | 0.0% |
| Q2 2022 | 14 | $652.0K | 872,855 | 5 | 2 | 4 | 0.0% |
| Q1 2022 | 11 | $1.5M | 1,209,937 | 2 | 2 | 4 | 0.0% |
| Q4 2021 | 10 | $1.4M | 1,209,052 | 1 | 5 | 2 | 0.0% |
| Q3 2021 | 9 | $2.5M | 1,212,130 | 2 | 3 | 1 | 0.0% |
| Q2 2021 | 10 | $7.4M | 2,445,105 | 4 | 3 | 2 | 0.0% |
| Q1 2021 | 7 | $4.4M | 1,335,221 | 6 | 0 | 0 | 0.0% |
| Q4 2020 | 3 | $714.0K | 225,456 | 3 | 0 | 0 | 0.0% |